Keywords: Novartis, Aliskiren, EMA, Benefits/risks, Rasilez, Tekturna

EMA reviewing Novartis aliskiren-containing drugs

Article | 23 December 2011

The European Medicines Agency is reviewing aliskiren-containing medicines, approved for the treatment of essential hypertension, to assess the impact of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

Rasilez

Aliskiren Tablets

Tekturna

Go to drug listing